Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study of uliledlimab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback